Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.

Regidor PA, Regidor M, Schmidt M, Ruwe B, Lübben G, Förtig P, Kienle E, Schindler AE

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology1 Jun 2001Cited by 30 (Europe PMC)

PMID11447732DOI10.1080/gye.15.3.202.209PepBankPUB-11447732

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with severe endometriosis, post-treatment r-AFS scores were significantly lower with leuprorelin than lynestrenol.
In plain wordsIn women with severe endometriosis, disease scores after treatment were lower with leuprorelin than lynestrenol.
Peptide
Leuprolide
Outcome
DecreasePost-treatment r-AFS score
Study
n = 48
Comparator
Lynestrenol 5 mg orally twice per day
Analysis
Primary
Outcome group
Endometriosis Severity · Reproductive and sexual health
Studied dose
3.75 mg per month · subcutaneous · 6 monthsAs given in this study (human).
Measurements
r-AFS score
11.5 points
LAD
r-AFS score
25.5 points
LYN
P value
0.000014
between groups
Source sentences
Summary
After the medical treatment a mean value of 11.5 points was observed in the LAD group compared with a mean value of 25.5 in the LYN group. This difference was statistically significant (p = 0.000014, Wilcoxon test).
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-eight women with postoperative r-AFS scores I-IV were evaluated in an open prospective randomized study between 1996 and 1998. All the participants underwent a first-look laparoscopy with resection of endometriotic lesions and six months' therapy with one of the above mentioned drugs, and a fu…
Report a problemFND-1144773202
02HumanRandomized controlled trialEfficacy outcome
In women with severe endometriosis, improvement in dysmenorrhea, chronic pelvic pain and dyspareunia was more pronounced with leuprorelin than lynestrenol.
In plain wordsIn women with severe endometriosis, menstrual pain, chronic pelvic pain and pain during sex improved more with leuprorelin than lynestrenol.
Peptide
Leuprolide
Outcome
Direction not reportedDysmenorrhea, chronic pelvic pain and dyspareunia
Study
n = 48
Comparator
Lynestrenol 5 mg orally twice per day
Analysis
Secondary
Outcome group
Pain · Reproductive and sexual health
Studied dose
3.75 mg per month · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
The improvement in the symptoms of dysmenorrhea, chronic pelvic pain and dyspareunia was also more pronounced in the LAD-treated group.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-eight women with postoperative r-AFS scores I-IV were evaluated in an open prospective randomized study between 1996 and 1998. All the participants underwent a first-look laparoscopy with resection of endometriotic lesions and six months' therapy with one of the above mentioned drugs, and a fu…
Report a problemFND-1144773203
03HumanRandomized controlled trialEfficacy outcome
In women with severe endometriosis, leuprorelin suppressed serum estradiol more than lynestrenol after six months.
In plain wordsIn women with severe endometriosis, leuprorelin suppressed estradiol more than lynestrenol after six months.
Peptide
Leuprolide
Outcome
DecreaseSerum 17 beta-estradiol
Study
n = 48
Comparator
Lynestrenol 5 mg orally twice per day
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg per month · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Mean estradiol
27.7 pg/ml
LAD
Mean estradiol
42.6 pg/ml
LYN
Mean estradiol variability (+/- as written)
9.3 pg/ml
LAD
Mean estradiol variability (+/- as written)
59.3 pg/ml
LYN
Source sentences
Summary
LAD was more effective than LYN in the suppression of circulating serum 17 beta-estradiol levels after 6 months of treatment (mean 27.7 +/- 9.3 pg/ml versus 42.6 +/- 59.3 pg/ml).
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-eight women with postoperative r-AFS scores I-IV were evaluated in an open prospective randomized study between 1996 and 1998. All the participants underwent a first-look laparoscopy with resection of endometriotic lesions and six months' therapy with one of the above mentioned drugs, and a fu…
Report a problemFND-1144773204
04HumanNon-randomized trialEfficacy outcome
In women with severe endometriosis, leuprorelin significantly reduced r-AFS scores from the postoperative pretreatment assessment.
In plain wordsIn women with severe endometriosis, leuprorelin reduced disease scores compared with postoperative pretreatment scores.
Peptide
Leuprolide
Outcome
DecreaseChange in r-AFS score
Study
n: not reported in source
Comparator
Postoperative pretreatment score
Analysis
Primary
Outcome group
Endometriosis Severity · Reproductive and sexual health
Studied dose
3.75 mg per month · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Baseline r-AFS score
21.8 points
LAD
Post-treatment r-AFS score
11.5 points
LAD
Source sentences
Summary
The six months' treatment with LAD or LYN led to a significant reduction of the r-AFS score points in both groups. The mean r-AFS score in points for the LAD group after the first-look laparoscopy was 21.8 and was 27.2 for the LYN group. After the medical treatment a mean value of 11.5 points was ob…
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-eight women with postoperative r-AFS scores I-IV were evaluated in an open prospective randomized study between 1996 and 1998. All the participants underwent a first-look laparoscopy with resection of endometriotic lesions and six months' therapy with one of the above mentioned drugs, and a fu…
Report a problemFND-1144773201

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.